Clinical and Scintigraphic Data of Patients with COPD and Control Subjects
| Subject no. | Age (y) | Duration (y) | FEV1.0 (L) (% predicted) | 123I-MIBG scintigraphic data | Medical therapy | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (L/M)E | (L/M)D | WR (%) | TP (mg) | OB (mg) | Steroid | |||||||||||||
| COPD patients | ||||||||||||||||||
| 1 | 77 | 6 | 0.76 (34.7) | 1.17 | 1.15 | 21.8 | 200 | 0.6 | — | |||||||||
| 2 | 60 | 2 | 1.24 (43.4) | 1.28 | 1.20 | 34.7 | 400 | — | — | |||||||||
| 3 | 73 | 22 | 0.92 (43.8) | 1.28 | 1.22 | 29.5 | 400 | — | — | |||||||||
| 4 | 83 | 15 | 0.64 (40.5) | 1.22 | 1.16 | 24.9 | — | 0.6 | — | |||||||||
| 5 | 83 | 14 | 0.50 (36.5) | 1.33 | 1.29 | 22.8 | 200 | 0.6 | FP 800 μg | |||||||||
| 6 | 77 | 12 | 0.87 (40.7) | 1.39 | 1.28 | 28.7 | — | — | — | |||||||||
| 7 | 63 | 8 | 0.99 (36.7) | 1.39 | 1.24 | 25.3 | 400 | 0.6 | — | |||||||||
| 8 | 81 | 7 | 0.80 (48.2) | 1.42 | 1.27 | 28.4 | 200 | 0.6 | FP 800 μg | |||||||||
| 9 | 67 | 1 | 1.03 (49.3) | 1.07 | 1.03 | 27.1 | — | — | — | |||||||||
| 10 | 70 | 7 | 1.53 (64.6) | 1.34 | 1.25 | 26.3 | 400 | 0.4 | — | |||||||||
| 11 | 70 | 25 | 0.41 (17.8) | 0.97 | 0.99 | 25.2 | 400 | 0.6 | — | |||||||||
| 12 | 75 | 9 | 1.04 (52.8) | 1.07 | 1.10 | 21.6 | 400 | 0.6 | — | |||||||||
| 13 | 66 | 14 | 0.61 (30.8) | 1.29 | 1.20 | 32.8 | 200 | 0.6 | — | |||||||||
| 14 | 74 | 18 | 0.37 (16.6) | 0.90 | 0.96 | 19.1 | 300 | 0.8 | — | |||||||||
| 15 | 69 | 6 | 0.93 (40.3) | 1.16 | 1.21 | 22.3 | 400 | — | MP 4 mg | |||||||||
| 16 | 44 | 5 | 0.88 (24.8) | 1.35 | 1.21 | 38.1 | — | 0.4 | FP 400 μg | |||||||||
| 17 | 79 | 5 | 0.74 (42.0) | 1.22 | 1.14 | 29.5 | 400 | 0.8 | — | |||||||||
| 18 | 74 | 27 | 0.51 (24.4) | 1.46 | 1.32 | 34.9 | 200 | 0.6 | MP 4 mg | |||||||||
| 19 | 77 | 3 | 1.19 (54.6) | 1.10 | 1.09 | 24.0 | 200 | 0.6 | — | |||||||||
| 20 | 73 | 12 | 0.57 (32.4) | 1.12 | 1.08 | 30.9 | 400 | — | FP 400 μg | |||||||||
| 21 | 75 | 2 | 2.19 (104.3) | 1.69 | 1.50 | 32.8 | 200 | 0.6 | — | |||||||||
| 22 | 74 | 5 | 1.08 (51.9) | 1.53 | 1.37 | 36.5 | 400 | 0.8 | — | |||||||||
| 23 | 79 | 20 | 0.73 (36.5) | 1.35 | 1.28 | 20.4 | 400 | — | PSL 7.5 mg | |||||||||
| 24 | 74 | 1 | 2.63 (122.3) | 1.22 | 1.21 | 21.9 | — | — | — | |||||||||
| 25 | 77 | 1 | 0.74 (37.6) | 1.28 | 1.25 | 25.6 | — | — | — | |||||||||
| Control subjects | ||||||||||||||||||
| 1 | 52 | — | 3.67 (115.8) | 1.71 | 1.43 | 39.1 | — | — | — | |||||||||
| 2 | 75 | — | 1.61 (95.3) | 1.51 | 1.28 | 24.6 | — | — | — | |||||||||
| 3 | 73 | — | 2.23 (119.3) | 1.54 | 1.30 | 43.9 | — | — | — | |||||||||
| 4 | 66 | — | 3.1 (127.0) | 1.65 | 1.34 | 40.0 | — | — | — | |||||||||
| 5 | 87 | — | 2.78 (178.2) | 1.52 | 1.41 | 29.3 | — | — | — | |||||||||
| 6 | 82 | — | 2.42 (114.7) | 1.46 | 1.31 | 26.7 | — | — | — | |||||||||
| 7 | 78 | — | 2.81 (126.6) | 1.52 | 1.25 | 32.1 | — | — | — | |||||||||
| 8 | 73 | — | 2.44 (117.3) | 1.60 | 1.32 | 36.8 | — | — | — | |||||||||
| 9 | 73 | — | 3.42 (155.5) | 1.37 | 1.21 | 32.7 | — | — | — | |||||||||
| 10 | 64 | — | 3.34 (126.5) | 1.65 | 1.51 | 31.1 | — | — | — | |||||||||
| 11 | 50 | — | 3.90 (127.5) | 1.66 | 1.38 | 38.0 | — | — | — | |||||||||
| 12 | 67 | — | 2.81 (121.1) | 1.36 | 1.25 | 35.9 | — | — | — | |||||||||
(L/M)E = mean uptake ratio of 123I-MIBG of bilateral lungs to mediastinum in early image; (L/M)D = mean uptake ratio of 123I-MIBG of bilateral lungs to mediastinum in delayed image; WR = mean washout rate of 123I-MIBG of bilateral lungs between early and delayed image; TP = oral administration of theophylline per day; OB = inhaled administration of oxitropium bromide per day; FP = inhaled administration of fluticasone propionate per day; MP = oral administration of methylprednisolone per day; PSL = oral administration of prednisolone per day.